Overview
Dexpanthenol is an alcohol derivative of pantothenic acid, a component of the B complex vitamins and an essential component of a normally functioning epithelium. Dexpanthenol is enzymatically cleaved to form pantothenic acid, which is an essential component of Coenzyme A, which acts as a cofactor in many enzymatic reactions that are important for protein metabolism in the epithelium. Due to its good penetration and high local concentrations, dexpanthanol is used in many topical products, such as ointments and lotions for treatment of dermatological conditions to relieve itching or promote healing. Dermatological effects of the topical use of dexpanthenol include increased fibroblast proliferation and accelerated re-epithelialization in wound healing. Furthermore, it acts as a topical protectant, moisturizer, and has demonstrated anti-inflammatory properties . Dexpanthenol is also available as a racemic mixture containing both the dextrorotatory form (dexpanthenol) and the levorotatory form (levopanthenol) as Panthenol. While pantothenic acid is optically active, only the dextrorotatory form (dexpanthenol) is biologically active.
Background
Dexpanthenol is an alcohol derivative of pantothenic acid, a component of the B complex vitamins and an essential component of a normally functioning epithelium. Dexpanthenol is enzymatically cleaved to form pantothenic acid, which is an essential component of Coenzyme A, which acts as a cofactor in many enzymatic reactions that are important for protein metabolism in the epithelium. Due to its good penetration and high local concentrations, dexpanthanol is used in many topical products, such as ointments and lotions for treatment of dermatological conditions to relieve itching or promote healing. Dermatological effects of the topical use of dexpanthenol include increased fibroblast proliferation and accelerated re-epithelialization in wound healing. Furthermore, it acts as a topical protectant, moisturizer, and has demonstrated anti-inflammatory properties . Dexpanthenol is also available as a racemic mixture containing both the dextrorotatory form (dexpanthenol) and the levorotatory form (levopanthenol) as Panthenol. While pantothenic acid is optically active, only the dextrorotatory form (dexpanthenol) is biologically active.
Indication
Injection: Prophylactic use immediately after major abdominal surgery to minimize the possibility of paralytic ileus. Intestinal atony causing abdominal distention; postoperative or postpartum retention of flatus, or postoperative delay in resumption of intestinal motility; paralytic ileus. Topical: This medication is used as a moisturizer to treat or prevent dry, rough, scaly, itchy skin and minor skin irritations (e.g., diaper rash, skin burns from radiation therapy).
Associated Conditions
- Allergic Rhinitis (AR)
- Bursitis
- Canker Sore
- Contusions
- Dermabrasion
- Diaper Rash
- Dry Skin
- Edema
- Hoarseness
- Inflammation
- Inflammation of Mouth
- Insect Bites
- Lateral Epicondylitis
- Lesions of the Mucous Membranes
- Nasal Congestion
- Pharyngeal inflammation
- Pruritus
- Respiratory Tract Infections (RTI)
- Seasonal Allergic Rhinitis
- Sinusitis
- Skin Roughness
- Sore Throat
- Sunburn
- Tendinitis
- Tooth Extraction Site Healing
- Traumatic Injuries caused by Dental Prosthesis
- Urticaria
- Vitamin Deficiency
- Wounds caused by Surgery, Oral of the Tonsils
- Dry, cracked skin
- Dryness of the nose
- Superficial Conjunctival injuries
- Superficial Corneal injuries
- Superficial Traumatic Injuries of the Nasal Mucosa
- Superficial Wounds
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2020/01/07 | Phase 1 | Terminated | |||
2018/05/09 | Phase 1 | Completed | |||
2017/03/30 | Phase 3 | Completed | |||
2016/04/12 | Phase 4 | Completed | |||
2011/03/21 | Phase 2 | UNKNOWN | |||
2009/04/22 | Phase 1 | Completed | |||
2009/03/10 | Phase 4 | Completed | |||
2009/02/09 | Phase 2 | Completed | |||
2009/02/09 | Phase 2 | Completed | |||
2008/04/18 | Phase 3 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Sandoz Inc | 54643-9023 | INTRAVENOUS | 5 mg in 5 mL | 10/28/2016 | |
Sandoz Inc | 54643-9015 | INTRAVENOUS | 15 mg in 10 mL | 10/28/2016 | |
Dr. Donna Restivo DC | 62185-0059 | ORAL | 6 [hp_X] in 1 mL | 5/23/2025 | |
Carilion Materials Management | 68151-1928 | ORAL | 5 mg in 1 1 | 11/11/2013 | |
Raw Materials International Overseas LLC | 69877-026 | INTRAMUSCULAR, INTRAVENOUS | 2 mg in 1 mL | 12/31/2015 | |
Merit Pharmaceutical | 30727-300 | INTRAMUSCULAR, INTRAVENOUS | 2 mg in 1 mL | 12/4/2020 | |
Sandoz Inc | 54643-7874 | INTRAVENOUS | 15 mg in 10 mL | 10/28/2016 | |
Sandoz Inc | 54643-5650 | INTRAVENOUS | 15 mg in 10 mL | 3/17/2016 | |
PureTek Corporation | 59088-180 | ORAL | 15 mg in 1 1 | 1/11/2023 | |
FLON LABORATORIES LLC | 71414-225 | INTRAVENOUS, INTRAMUSCULAR | 2 mg in 1 mL | 9/29/2017 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
TAMIPOOL FOR INJECTION | SIN11849P | INJECTION, POWDER, FOR SOLUTION | 15 mg/vial | 3/15/2002 | |
CERNEVIT FOR INJECTION | SIN11975P | INJECTION, POWDER, FOR SOLUTION | 17.25 mg/vial | 6/5/2002 | |
ENZYPLEX TABLET | SIN06211P | ENTERIC COATED TABLET | 5 mg | 5/3/1991 | |
IBERET-FOLIC-500 TABLET | SIN05447P | TABLET, FILM COATED | 10 mg | 2/19/1991 | |
SOLUVIT N FOR INFUSION | SIN05209P | INJECTION, POWDER, FOR SOLUTION | 16.5mg /vial | 11/14/1990 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
CERNEVIT FOR INJ | N/A | N/A | N/A | 4/18/2008 | |
CORNEREGEL EYE GEL 50MG/G | N/A | N/A | N/A | 7/23/2007 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
BIOLOGICAL THERAPIES B-DOSE PLUS 10ml injection vial | 47755 | Medicine | A | 1/31/1994 | |
BIOLOGICAL THERAPIES B-DOSE AE 2mL injection vial | 22269 | Medicine | A | 10/8/1991 | |
BIOLOGICAL THERAPIES B-DOSE FORTE 2.5mL injection vial | 22408 | Medicine | A | 10/8/1991 | |
EverMax Dyneaway | 422951 | Medicine | A | 9/28/2023 | |
DyneAway | 465034 | Medicine | A | 10/21/2024 | |
BIOLOGICAL THERAPIES B-DOSE AE 10mL injection vial | 47753 | Medicine | A | 1/31/1994 | |
BIOLOGICAL THERAPIES B DOSE FORTE 10mL injection vial | 47762 | Medicine | A | 1/31/1994 | |
Refresh Spritz | 426715 | Medicine | A | 10/24/2023 | |
AllClear | 140382 | Medicine | A | 6/13/2007 | |
HIVITA HAPPY ENERGY LIQUID MULTIVITAMIN FOR KIDS | 401154 | Medicine | A | 12/15/2022 |